J&J advances Stelara succession scheme with key FDA nod for Tremfya in Crohn's disease
The FDA approved Tremfya as an induction therapy in adults with moderately to severely active Crohn’s disease, making the drug the first IL-23 inhibitor cleared for both subcutaneous and intravenous treatment of the inflammatory bowel disease in the U.S.
The FDA approved Tremfya as an induction therapy in adults with moderately to severely active Crohn’s disease, making the drug the first IL-23 inhibitor cleared for both subcutaneous and intravenous treatment of the inflammatory bowel disease in the U.S.
